Alvin J. Siteman Cancer Center

Vesica Health Announces Publication of Study Demonstrating AssureDx Meaningfully Improves Identification of Hematuria Patients at High Risk for Bladder Cancer

Retrieved on: 
Monday, October 9, 2023
OTX1, Probability, AUA, Physician, Department of Urology, University of Virginia, National Capital FreeNet, American Urological Association, TERT, Johns Hopkins University, DNA, Risk, AUC, Capital city, Microhematuria, Urology, Hematuria, Health, HEALTH, Cancer, Carcinoma, TWIST1, Alvin J. Siteman Cancer Center, HRAS, DNA methylation, European Urology, Medical school, Patient, Bladder cancer, FGFR3, Liquid biopsy, Risk assessment, Barnes-Jewish Hospital

The study titled "A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines" was published in the journal European Urology Oncology.

Key Points: 
  • The study titled "A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines" was published in the journal European Urology Oncology.
  • The study analyzed a prospectively collected cohort of 838 hematuria subjects previously tested by AssureDx.
  • Subjects were classified into the AUA risk categories for bladder cancer based on their sex, age, and type of hematuria, also known as urothelial carcinoma (UC).
  • "Publication of this pivotal study in a leading international urology journal, demonstrating AssureDx enhances the AUA Guidelines, underscores the importance of the test for risk stratification of hematuria patients and identification of those at increased risk for bladder cancer," stated Christopher Thibodeau, Chief Executive Officer of Vesica Health.

Breast cancer expert shares ways to lower risk, catch cancer early

Retrieved on: 
Thursday, September 21, 2023
Linda, Exercise, Breast Cancer Awareness Month, Dance, Maintenance, Obesity, Tennis, Interview, Life, Genetics, Anxiety, In Honor: A Compilation to Beat Cancer, Cancer, Genetic testing, Woman, Breast, Research, Multimedia, Alvin J. Siteman Cancer Center, Breast self-examination, National Cancer Institute, Walking, MD, Patient, Risk, Diagnosis, LOMA, Nipple discharge, Gene, National Cancer Institute (Egypt), Breast cancer, Disease, Dietary supplement, Birth control, Nursing, Medical imaging

LOMA LINDA, Calif., Sept. 21, 2023 /PRNewswire-PRWeb/ -- A woman living in the United States today faces a one in eight chance of being diagnosed with breast cancer at some time during her life, according to estimates from National Cancer Institute's reports. Prevention and early detection are the best ways to prepare to handle risks associated with breast cancer, says Halley Vora, MD, medical director of the Breast Health Center at Loma Linda University Cancer Center.

Key Points: 
  • Prevention and early detection are the best ways to prepare to handle risks associated with breast cancer, says Halley Vora, MD , medical director of the Breast Health Center at Loma Linda University Cancer Center.
  • — Halley Vora, MD
    In anticipation of October's Breast Cancer Awareness Month, Vora shares four steps you can take at home and in-clinic to prevent breast cancer or catch it early on.
  • This breast imaging can detect early signs of cancer years before symptoms of the cancer can be felt, Vora says.
  • Delaying breast cancer screening will delay a diagnosis of breast cancer.

Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial

Retrieved on: 
Sunday, September 10, 2023
Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, PRS, DCR, International Association, Lung cancer, ILD, NSCLC, Carboplatin, Lung, AstraZeneca, Alvin J. Siteman Cancer Center, HIV disease progression rates, MD, Patient, EGFR, DXD, Daiichi Sankyo, Anemia, Washington University School of Medicine, ADC, Spacecraft, Thrombocytopenia, ORR, Conference, TSE, Disease, ALK, Pharmaceutical industry, Fine chemical, Durvalumab

These data were presented today during a late-breaking oral presentation ( OA05.06 ) at the IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC23).

Key Points: 
  • These data were presented today during a late-breaking oral presentation ( OA05.06 ) at the IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC23).
  • Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).
  • Response rates were higher in patients receiving datopotamab deruxtecan plus durvalumab and carboplatin (triplet; n=13) which demonstrated an ORR of 76.9% (95% CI: 46.2-95.0), including 10 PRs and a DCR of 92.3% (95% CI: 64.0-99.8).
  • “The TROPION-Lung04 results offer preliminary evidence for the efficacy of datopotamab deruxtecan in combination with durvalumab and chemotherapy in first-line advanced non-small cell lung cancer with no new safety signals.

THERESA'S RESEARCH FOUNDATION ANNOUNCES NEW WHITE PAPER AND CELEBRATES 10 YEARS OF BRINGING CANCER RESEARCHERS AND PATIENT ADVOCATES TOGETHER

Retrieved on: 
Monday, August 21, 2023
Steps, Linda, Mayo Clinic, University, Education, Friends, Accidental Death and Disability: The Neglected Disease of Modern Society, White paper, Johns Hopkins School of Medicine, Metastatic breast cancer, Cancer, Research, Doctor of Philosophy, Alvin J. Siteman Cancer Center, University of Utah, Basic research, Huntsman Cancer Institute, Professor, Patient, Breast cancer, Baylor College of Medicine, Odds, Friends of Cancer Research, Family, Conference, Nursing, Birth control, Pharmaceutical industry

This White Paper highlights Findings from the 2022 Metastatic Breast Cancer Research Conference and is a follow up to our publication in npj Breast Cancer .

Key Points: 
  • This White Paper highlights Findings from the 2022 Metastatic Breast Cancer Research Conference and is a follow up to our publication in npj Breast Cancer .
  • "Patient advocates and cancer researchers working together is critical for better research that leads to improved patient outcomes.
  • "I'm thrilled to welcome so many outstanding breast cancer researchers from across the world to the 10th annual Metastatic Breast Cancer Research Conference.
  • The Foundation will host a celebration to mark its 10-year milestone at this year's Metastatic Breast Cancer Research Conference in Park City, Utah on August 31.

New Study in JNCCN Highlights Rapid Adoption of Clinical Research Results into Chemotherapy Prescribing Patterns

Retrieved on: 
Monday, August 7, 2023
Mayo Clinic, Clarivate, COVID-19, Weakness, Hypoesthesia, African Americans, National Comprehensive Cancer Network, Research, Black, Associate, MS, NCCN, CAPOX, Alvin J. Siteman Cancer Center, DO, Publication, Journal of the National Comprehensive Cancer Network, Patient, Manuscript, FOLFOX, Cancer, Washington University School of Medicine, Kidney, Peripheral neuropathy, Financial toxicity, IDEA, Clinical professor, Oncology, III, Colorectal cancer, Barnes-Jewish Hospital, Dentistry, Pharmaceutical industry, MD

PLYMOUTH MEETING, Pa., Aug. 7, 2023 /PRNewswire/ -- New research in the August 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network evaluates how an important analysis on local-regionally advanced colon cancer adjuvant chemotherapy impacted prescribing patterns. The IDEA collaboration included more than 12,000 patients with Stage III colon cancer across 6 randomized phase 3 trials in a planned pooled analysis, to determine how three or six months of post-surgery chemotherapy—either a combination of capecitabine/oxaliplatin (CAPOX) or fluorouracil/leucovorin/oxaliplatin (FOLFOX)—impacted outcomes.1 The current JNCCN study revealed that after the full publication of IDEA, the percentage of patients treated with CAPOX rose from 14% to 48%. Also, 45.2% of patients were prescribed adjuvant therapy for only three months after IDEA, compared to just 5.6% before.

Key Points: 
  • Also, 45.2% of patients were prescribed adjuvant therapy for only three months after IDEA, compared to just 5.6% before.
  • After publication of IDEA, 45.2% of patients were prescribed adjuvant therapy for only 3 months compared to 5.6% before.
  • "Our study results showed a significant increase in planning for three months of adjuvant chemotherapy after the presentation of IDEA.
  • Complimentary access to " Changes in Prescribing Patterns in Stage III Colon Cancer " is available until November 10, 2023.

Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Thursday, May 25, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, GIST, DNA, University, Diarrhea, Progression-free survival, Sunitinib, Survival, OS, Cancer, AP, Toxicity, Associate, PFS, Mutation, Teaching hospital, QD, ASCO, KIT, Hypertension, Hair, Myalgia, American Society of Clinical Oncology, HIV disease progression rates, Patient, Clinical research, Annual general meeting, German Cancer Research Center, University of Duisburg-Essen, Neoplasm, ITT, Gastrointestinal stromal tumor, Society, Alvin J. Siteman Cancer Center, Clinical, ORR, IRR, Safety, Fatigue, Pharmaceutical industry, Medical imaging, Typesetting, Jet fuel, Bookkeeping

“As we prepare to initiate our INSIGHT pivotal Phase 3 study of QINLOCK versus sunitinib in second-line GIST patients with KIT exon 11 and 17/18 mutations, we are excited to share details on the study design and additional supporting data from the INTRIGUE study.

Key Points: 
  • “As we prepare to initiate our INSIGHT pivotal Phase 3 study of QINLOCK versus sunitinib in second-line GIST patients with KIT exon 11 and 17/18 mutations, we are excited to share details on the study design and additional supporting data from the INTRIGUE study.
  • In the all-patient intent-to-treat population, overall survival was 35.5 months in the QINLOCK arm and 30.9 months in the sunitinib arm.
  • The favorable safety profile was consistent with our primary analysis, with fewer patients on QINLOCK experiencing Grade 3/4 treatment-emergent adverse events compared to sunitinib.
  • Presentation details are as follows:
    Title: Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.

Prostatype Genomics appoints Professor Gerald Andriole as Chief Medical Officer

Retrieved on: 
Friday, May 5, 2023
Society, Prostate cancer, Genomics, Brigham and Women's Hospital, Research, Lung, Thomas Jefferson University, Washington University in St. Louis, Harvard Medical School, National Cancer Institute, Committee, Johns Hopkins University, Patient, Physician, Alvin J. Siteman Cancer Center, Joint Task Force National Capital Region Medical, Washington University School of Medicine, Neoplasm, Department of Urology, University of Virginia, Hospital, Capital city, Distinguishing, Barnes-Jewish Hospital, Pharmaceutical industry, Nursing, Urology, MD

SOLNA, Sweden, May 5, 2023 /PRNewswire/ -- Prostatype Genomics AB announced today that Professor Gerald Andriole has been appointed as global Chief Medical Officer at Prostatype Genomics.

Key Points: 
  • SOLNA, Sweden, May 5, 2023 /PRNewswire/ -- Prostatype Genomics AB announced today that Professor Gerald Andriole has been appointed as global Chief Medical Officer at Prostatype Genomics.
  • With more than 35 years in urology, Professor Andriole brings a wealth of experience and expertise to Prostatype Genomics as the company works towards commercializing the Prostatype® test in the United States and globally.
  • Professor Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania.
  • Fredrik Persson CEO of Prostatype Genomics says "We are honored that Professor Andriole has decided to join Prostatype Genomics.

Researchers Show Lorlatinib is Safe and Effective for Patients with ALK-Driven Relapsed/Refractory High-Risk Neuroblastoma

Retrieved on: 
Monday, April 3, 2023
Army, Neoplasm, Band of Parents, Science, Discovery, MD, Patient, Disease, Children's Hospital of Philadelphia, ALK, Neuroblastoma, Emory University, St. Baldrick's Foundation, Alex's Lemonade Stand Foundation, Pediatrics, Consortium, CHOP, Wipe Out Kids' Cancer, Crizotinib, Research, Lung cancer, Pfizer, MYCN, Anaplastic lymphoma kinase, DOI, Hospital, FDA, NCI, Alvin J. Siteman Cancer Center, Safety, New Approach to Appraisal, Emory University School of Medicine, Winship Cancer Institute, Lipid, Development of the human body, COG, Children's Oncology Group, Weight gain, National Cancer Institute, International Society, Cancer, Adolescence, Band, Ronan (song), Clinical trial, Abdomen, Pharmaceutical industry, Medical imaging, Child, Nature Medicine, Parent

PHILADELPHIA, April 3, 2023 /PRNewswire/ -- In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children's Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma. The findings, published today in Nature Medicine, have led to a major amendment in a phase 3 Children's Oncology Group (COG) clinical trial, which has incorporated lorlatinib for newly diagnosed ALK-driven high-risk neuroblastoma, as well as a planned amendment to the European phase 3 trial in collaboration with the International Society of Paediatric Oncology European Neuroblastoma (SIOPEN).

Key Points: 
  • The difficulties we experienced in targeting ALK with crizotinib in neuroblastoma motivated us to find a more potent ALK inhibitor.
  • In the phase 1 NANT trial, researchers found that lorlatinib given alone or in combination with chemotherapy was safe and tolerable in pediatric, adolescent, and adult patients with relapsed/refractory ALK-driven neuroblastoma.
  • The researchers noted that younger patients treated with lorlatinib alone – particularly those with amplification of an oncogene called MYCN – had fewer responses compared to older patients.
  • "Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase I trial results," Nature Medicine, April 3, 2023, DOI: 10.1038/s41591-023-02297-5

PreludeDx™ Presents New Data at the 40th Annual Miami Breast Cancer Conference Identifying Which Patients with DCIS May Be Undertreated Based on Clinicopathologic Factors Alone

Retrieved on: 
Thursday, March 2, 2023
Patient, CP, Additive effect, Active surveillance of low-risk papillary thyroid microcarcinoma, Washington University School of Medicine, Woman, HT, DCIS, MBCC, FACS, Therapy, Fontainebleau Miami Beach, Conference, Alvin J. Siteman Cancer Center, Breast, Clinical research, MSKCC, Cleveland Clinic, Ductal carcinoma, Memorial Sloan Kettering Cancer Center, RT, Medicine, Poster, IBR, Comparative oncology, Nomogram, BCS, Medical imaging, Nursing, Pharmaceutical industry, Radiation therapy, MD

LAGUNA HILLS, Calif., March 2, 2023 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it will be presenting data comparing risk stratification and radiation benefit (RT) for patients with ductal carcinoma in situ (DCIS) using DCISionRT™ with a clinicopathologic (CP) model similar to the Memorial Sloan Kettering Cancer Center (MSKCC) DCIS nomogram at the 40th Annual Miami Breast Cancer Conference (MBCC), being held on March 2 – 5, 2023 at the Fontainebleau Miami Beach.

Key Points: 
  • The study included 926 DCIS patients from four cohorts who were treated with breast conserving surgery (BCS) or BCS + radiation therapy (RT).
  • The study compared MSKCC DCIS nomogram-like model with the DCISionRT 7-gene biosignature.
  • "DCISionRT provides us the clinical evidence to identify which DCIS patients, despite having low-risk clinicopathologic features, can actually benefit from RT and which patients may safely omit RT."
  • The registry includes females 26 and older who are diagnosed with DCIS and are candidates for BCS and eligible for RT.

AltruBio Presents New Positive Data from its Completed Phase 1b Study Evaluating ALTB-168 in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022

Retrieved on: 
Saturday, December 10, 2022
Ulcerative colitis, Cell, Assistant, Clinical trial, Degenerative disease, SAN, Inflammation, Alvin J. Siteman Cancer Center, Graft-versus-host disease, Assistant professor, Safety, News, Biotechnology, CRS, Pharmacokinetics, ASH, ORR, Psoriasis, Medical College of Wisconsin, Saint Francis Hospital & Medical Center, Society, Autoimmunity, IND, COR, Patient, Therapy, Pharmaceutical industry, Vaccine, Aluminium

SAN FRANCISCO, Dec. 10, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, today announced the presentation of new data from its completed Phase 1b clinical trial evaluating ALTB-168 in patients with steroid-refractory (SR-aGVHD) or treatment-refractory (TR-aGVHD) acute graft-versus-host-disease at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022 in New Orleans, La. The data will be presented in a poster by clinical trial investigator, Sameem Abedin, M.D., Assistant Professor, Medical College of Wisconsin, Cancer Center, Froedtert Hospital Medical.

Key Points: 
  • The data will be presented in a poster by clinical trial investigator, Sameem Abedin, M.D., Assistant Professor, Medical College of Wisconsin, Cancer Center, Froedtert Hospital Medical.
  • “60% of patients with aGVHD do not respond to corticosteroids as first line treatment, and those that do not respond to any treatment have extremely poor outcomes.
  • The clinical results in this indication validated the strategy of targeting PSGL-1 to control chronically active T cell-related immunological disorders and restore immune balance.
  • ALTB-268 has the same mechanism of action as ALTB-168 with a greater potency that allows for subcutaneous delivery enabling pursuit of different indications than ALTB-168.